Effects of Viral Eradication With Ledipasvir and Sofosbuvir, With or Without Ribavirin, on Measures of Fatigue in Patients With Chronic Hepatitis C Virus Infection.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Clinical Gastroenterology and Hepatology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.cgh.2015.07.035PMID 26241510
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Contribution of symptom clusters to multiple sclerosis consequences

  2015cited by this paper
• Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies

  2015cited by this paper
• Treatment with ledipasvir and sofosbuvir improves patient‐reported outcomes: Results from the ION‐1, ‐2, and ‐3 clinical trials

  2015cited by this paper
• Ribavirin restores IFNα responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes

  2015cited by this paper
• Ribavirin shows immunomodulatory effects on activated microglia

  2014cited by this paper
• Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

  2014cited by this paper
• Improvement of neurocognitive function in responders to an antiviral therapy for chronic hepatitis C

  2013cited by this paper
• Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study.

  2012cited by this paper
• Molecular signatures of peripheral blood mononuclear cells during chronic interferon-α treatment: relationship with depression and fatigue

  2011cited by this paper
• What is Fatigue? Pathological and Nonpathological Fatigue

  2010cited by this paper
• Cognitive efficiency is associated with endogenous cytokine levels in patients with chronic hepatitis C.

  2010cited by this paper
• Central Fatigue: Issues Related to Cognition, Mood and Behavior, and Psychiatric Diagnoses

  2010cited by this paper
• Cognitive Dysfunction in Chronic Hepatitis C: A Review

  2008cited by this paper
• Fatigue and Health-Related Quality of Life (HRQL) in Chronic Hepatitis C Virus Infection

  2007cited by this paper
• Self-Reported Fatigue and Depressive Symptoms as Main Indicators of the Quality of Life (QOL) of Patients Living with HIV and Hepatitis C: Implications for Clinical Management and Future Research

  2007cited by this paper
• Fatigue in liver disease: pathophysiology and clinical management.

  2006cited by this paper
• Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment

  2005cited by this paper
• The experience of fatigue for people living with hepatitis C.

  2003cited by this paper
• Clinical relevance of fatigue levels in cancer patients at a Veterans Administration Medical Center

  2002cited by this paper
• Fatigue in patients with chronic hepatitis C

  2002cited by this paper
• Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1

  2000cited by this paper
• Depression, fatigue, and functional disability in patients with chronic hepatitis C.

  2000cited by this paper
• Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease

  1999cited by this paper
• Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system.

  1997cited by this paper
• Central fatigue. Critical issues, quantification and practical implications.

  1995cited by this paper
• The MOS 36‐Item Short‐Form Health Survey (SF‐36): II. Psychometric and Clinical Tests of Validity in Measuring Physical and Mental Health Constructs

  1993cited by this paper
• Neurobiology of muscle fatigue.

  1992cited by this paper
• The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus.

  1989cited by this paper

• State-of-the-Art Review: Hepatitis C.

  2025cites this paper
• Assessment of fatigue and its impact in chronic liver disease.

  2024cites this paper
• Key points for the management of hepatitis C in the era of pan-genotypic direct-acting antiviral therapy

  2024cites this paper
• Severe, Persistent, Disruptive Fatigue Post-SARS-CoV-2 Disproportionately Affects Young Women

  2023cites this paper
• When and in Whom to Initiate HCV Therapy

  2023cites this paper
• When and in Whom to Initiate HCV Therapy

  2023cites this paper
• When and in Whom to Initiate HCV Therapy

  2023cites this paper
• When and in Whom to Initiate HCV Therapy

  2023cites this paper
• Symptoms of Liver Disease During Tenofovir Therapy With or Without Peginterferon: Results from the Hepatitis B Research Network Immune Active Trial

  2023cites this paper
• When and in Whom to Initiate HCV Therapy

  2022cites this paper
• When and in Whom to Initiate HCV Therapy

  2022cites this paper
• When and in Whom to Initiate HCV Therapy

  2022cites this paper
• The Potential Role of Fatigue in Identifying Patients with NASH and Advanced Fibrosis who Experience Disease Progression.

  2022cites this paper
• Pathogenesis and management of fatigue in primary biliary cholangitis

  2022cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B

  2021cites this paper
• Changes in clinical scenarios, management, and perspectives of patients with chronic hepatitis C after viral clearance by direct-acting antivirals

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• Hepatitis C Virus Infection in Children and Pregnant Women: An Updated Review of the Literature on Screening and Treatments

  2020cites this paper
• Evolution of Hepatitis C Virus Treatment During the Era of Sofosbuvir-Based Therapies: A Real-World Experience in France

  2020cites this paper
• Direct Acting Anti-Viral Drugs Improve Health-Related Quality of Life in Patients' with Hepatitis C

  2020cites this paper
• Neurologische Komplikationen der Hepatitis-C-Infektion

  2020cites this paper
• Health-related quality of life in Cuban patients with chronic liver disease: a real-world experience.

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• Test, Evaluate, Monitor

  2019cites this paper
• Test, Evaluate, Monitor

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• Consensus recommendations on the diagnosis and treatment of hepatitis c virus infection in sub Saharan Africa

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• Impact of Direct Acting Antiviral Agent Therapy upon Extrahepatic Manifestations of Hepatitis C Virus Infection

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• Quality of life in patients with hepatitis C. Importance of treatment.

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• Importance of fatigue and its measurement in chronic liver disease

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper